Quent Long Short Global Small Cap Fund LP Makes New $2.20 Million Investment in Amgen Inc. $AMGN

Quent Long Short Global Small Cap Fund LP acquired a new position in Amgen Inc. (NASDAQ:AMGN) in the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 6,731 shares of the medical research company’s stock, valued at approximately $2,203,000.

A number of other institutional investors and hedge funds have also modified their holdings of the company. West Family Investments Inc. lifted its stake in shares of Amgen by 1.1% in the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock worth $779,000 after buying an additional 30 shares during the last quarter. Viawealth LLC lifted its stake in shares of Amgen by 0.4% in the third quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock worth $2,023,000 after buying an additional 30 shares during the last quarter. LOM Asset Management Ltd lifted its position in shares of Amgen by 1.2% during the 3rd quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock worth $721,000 after purchasing an additional 30 shares during the last quarter. Smith Salley Wealth Management lifted its position in shares of Amgen by 0.3% during the 4th quarter. Smith Salley Wealth Management now owns 10,786 shares of the medical research company’s stock worth $3,530,000 after purchasing an additional 30 shares during the last quarter. Finally, Evergreen Private Wealth LLC lifted its position in shares of Amgen by 4.0% during the 4th quarter. Evergreen Private Wealth LLC now owns 785 shares of the medical research company’s stock worth $257,000 after purchasing an additional 30 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Trading Up 0.8%

Amgen stock opened at $348.62 on Friday. The business has a 50 day moving average price of $361.24 and a two-hundred day moving average price of $338.80. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The stock has a market cap of $188.14 billion, a price-to-earnings ratio of 24.50, a price-to-earnings-growth ratio of 3.62 and a beta of 0.47. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $391.29.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same quarter in the prior year, the firm posted $5.31 EPS. The company’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts forecast that Amgen Inc. will post 22.18 EPS for the current year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. Amgen’s dividend payout ratio is presently 70.84%.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Completed early-stage cancer study — Amgen announced completion of a Phase 1/2 MTAP‑null cancer combination study, a pipeline de‑risking milestone that could support long‑term value if follow‑up data are positive. Amgen Marks Key Milestone With Completion of Early MTAP-Null Cancer Combo Study
• Positive Sentiment: Analyst price‑target lift — Guggenheim nudged its price target to $351 (from $347) ahead of earnings, a modest endorsement that may support the stock despite the firm keeping a Neutral rating. Guggenheim Adjusts Amgen Inc. (AMGN) PT to $351, Cites Updated Model Ahead of Earnings
• Neutral Sentiment: CTO retirement and leadership realignment — Amgen announced David M. Reese, M.D. will retire as EVP & Chief Technology Officer effective June 30, with a strategic leadership realignment emphasizing integration of biology and technology; operationally notable but framed as orderly. AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER
• Neutral Sentiment: New/maintained Hold coverage — Bernstein and Canaccord Genuity are on Hold for AMGN (Canaccord initiated coverage with a Hold), indicating limited near‑term analyst conviction. Amgen (AMGN) Receives a Hold from Bernstein Canaccord Genuity initiates coverage of Amgen (AMGN) with hold recommendation
• Negative Sentiment: Q1 earnings expected to decline — previews from Zacks/Yahoo suggest Amgen lacks the setup for an earnings beat in the upcoming Q1 report, creating downside risk around the release. Earnings Preview: Amgen (AMGN) Q1 Earnings Expected to Decline
• Negative Sentiment: Insider selling — filings show roughly US$4.1M of insider share sales over the past year, which some investors interpret as a cautionary signal. Amgen Insiders Sell US$4.1m Of Stock, Possibly Signalling Caution

Wall Street Analyst Weigh In

Several research firms recently weighed in on AMGN. Daiwa Securities Group boosted their price objective on Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. Guggenheim boosted their price objective on Amgen from $347.00 to $351.00 and gave the stock a “neutral” rating in a research report on Thursday, April 9th. Jefferies Financial Group began coverage on Amgen in a research report on Tuesday, March 10th. They set a “hold” rating and a $350.00 price objective for the company. Wells Fargo & Company boosted their price objective on Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a research report on Thursday, March 19th. Finally, Piper Sandler upped their target price on shares of Amgen from $381.00 to $432.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $356.62.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.